Show simple item record

dc.contributor.authorQureshi, A
dc.date.accessioned2022-02-01T15:34:23Z
dc.date.available2022-02-01T15:34:23Z
dc.date.issued2021-05
dc.identifier.citationAl-Maqrashi, Z. et al. (2021) ‘Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study’, Sultan Qaboos University medical journal, 21(2), pp. e237–e243en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15149
dc.description.abstractObjectives: This study aimed to report the clinicopathological features, management and long-term outcomes of patients with gastrointestinal stromal tumours (GISTs) in Oman. Methods: This retrospective study was conducted on patients treated for GIST between January 2003 and December 2017 at three tertiary referral centres in Muscat, Oman. All patients with confirmed histopathological diagnoses of GIST and followed-up at the centres during this period were included. Relevant information was retrieved from hospital records until April 2019. Results: A total of 44 patients were included in the study. The median age was 55.5 years and 56.8% were female. The most common primary site of disease was the stomach (63.6%) followed by the jejunum/ileum (18.2%). Two patients (4.5%) had c-Kit-negative, discovered on GIST-1-positive disease. A total of 24 patients (54.5%) presented with localised disease and eight (33.3%) were classified as being at high risk of relapse. Patients with metastatic disease received imatinib in a palliative setting, whereas those with completely resected disease in the intermediate and high-risk groups were treated with adjuvant imatinib. Of the six patients (13.6%) with progressive metastatic disease, of which four had mutations on exon 11 and one on exon 9, while one had wild-type disease. Overall, rates of progression-free survival and overall survival (OS) at 100 months were 77.4% and 80.4%, respectively. Rates of OS for patients with localised and metastatic disease were 89.9% and 80.2%, respectively. Conclusion: The presenting features and outcomes of patients with GISTs in Oman were comparable to those reported in the regional and international literature.
dc.publisherSultan Qaboos University Medical Journalen_US
dc.subjectAdjuvant chemotherapyen_US
dc.subjectGastrointestinal stromal tumorsen_US
dc.subjectImatiniben_US
dc.subjectOmanen_US
dc.subjectProtein kinase inhibitorsen_US
dc.subjectProto-Oncogene proteins c-kiten_US
dc.subjectSurvival rateen_US
dc.titleClinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecord10.18295/squmj.2021.21.02.012en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFOA2022-02-01T15:34:24Z
refterms.panelUnspecifieden_US
html.description.abstractObjectives: This study aimed to report the clinicopathological features, management and long-term outcomes of patients with gastrointestinal stromal tumours (GISTs) in Oman. Methods: This retrospective study was conducted on patients treated for GIST between January 2003 and December 2017 at three tertiary referral centres in Muscat, Oman. All patients with confirmed histopathological diagnoses of GIST and followed-up at the centres during this period were included. Relevant information was retrieved from hospital records until April 2019. Results: A total of 44 patients were included in the study. The median age was 55.5 years and 56.8% were female. The most common primary site of disease was the stomach (63.6%) followed by the jejunum/ileum (18.2%). Two patients (4.5%) had c-Kit-negative, discovered on GIST-1-positive disease. A total of 24 patients (54.5%) presented with localised disease and eight (33.3%) were classified as being at high risk of relapse. Patients with metastatic disease received imatinib in a palliative setting, whereas those with completely resected disease in the intermediate and high-risk groups were treated with adjuvant imatinib. Of the six patients (13.6%) with progressive metastatic disease, of which four had mutations on exon 11 and one on exon 9, while one had wild-type disease. Overall, rates of progression-free survival and overall survival (OS) at 100 months were 77.4% and 80.4%, respectively. Rates of OS for patients with localised and metastatic disease were 89.9% and 80.2%, respectively. Conclusion: The presenting features and outcomes of patients with GISTs in Oman were comparable to those reported in the regional and international literature.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


Files in this item

Thumbnail
Name:
Clinicopathological Features and ...
Size:
416.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record